Evidence map›Paper›PMID 37239905›Full record

ArticleInternational journal of molecular sciences2023

Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation.

Annamaria Sandomenico, Alessia Ruggiero, Emanuela Iaccarino, Angela Oliver, Flavia Squeglia, Miguel Moreira, Luciana Esposito, Menotti Ruvo, Rita Berisio

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Annamaria SandomenicoInstitute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.ORCID 0000-0001-5255-3668
Alessia RuggieroInstitute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.ORCID 0000-0002-3508-385X
Emanuela IaccarinoInstitute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.ORCID 0000-0002-9073-0204
Angela OliverInstitute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
Flavia SquegliaInstitute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
Miguel MoreiraInstitute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.ORCID 0000-0003-1204-0416
Luciana EspositoInstitute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.ORCID 0000-0001-6431-2677
Menotti RuvoInstitute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.ORCID 0000-0001-5997-756X
Rita BerisioInstitute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.ORCID 0000-0001-5025-6483
Institute of Biostructure and Bioimaging · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD59 is an abundant immuno-regulatory human protein that protects cells from damage by inhibiting the complement system. CD59 inhibits the assembly of the Membrane Attack Complex (MAC), the bactericidal pore-forming toxin of the innate immune system. In addition, several pathogenic viruses, including HIV-1, escape complement-mediated virolysis by incorporating this complement inhibitor in their own viral envelope. This makes human pathogenic viruses, such as HIV-1, not neutralised by the complement in human fluids. CD59 is also overexpressed in several cancer cells to resist the complement attack. Consistent with its importance as a therapeutical target, CD59-targeting antibodies have been proven to be successful in hindering HIV-1 growth and counteracting the effect of complement inhibition by specific cancer cells. In this work, we make use of bioinformatics and computational tools to identify CD59 interactions with blocking antibodies and to describe molecular details of the paratope-epitope interface. Based on this information, we design and produce paratope-mimicking bicyclic peptides able to target CD59. Our results set the basis for the development of antibody-mimicking small molecules targeting CD59 with potential therapeutic interest as complement activators.

Indexed as

Complement System ProteinsHIV-1Binding Sites, AntibodyCD59 AntigensComplement Inactivating AgentsComplement Membrane Attack ComplexHumansCD59 AntigensCD59 protein, humanComplement Inactivating AgentsComplement Membrane Attack ComplexComplement System Proteinsanti-viralcancercomplementepitopeinfectionparatopepeptideprotein structure

Identifiers

PMID37239905
PMCPMC10218266
OpenAlexW4376138547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.